Health Canada has officially eliminated the finished product specification (FPS) submission requirement for Class II and Class III NHP product licence applications, streamlining the documentation that companies must submit when seeking market authorization for natural health products in Canada.
The change, introduced under NNHPD Bulletin 11 as part of a broader effort to modernize the Natural Health Products Directorate (NHPD) application process, is expected to reduce administrative burden for applicants and shorten review timelines.
This update to the FPS submission requirement for NHP product licence applications reflects a shift in how Health Canada approaches pre-market review. Rather than requiring detailed finished product specifications at the application stage, the regulator will rely on other existing quality controls and post-market oversight mechanisms. For companies with active or pending submissions, the practical implications are significant.
What Has Changed
Previously, applicants for a Class II or Class III NHP product licence were required to include a completed FPS document in their submission package. The FPS contained detailed information about the finished dosage form, including specifications for identity, purity, potency, and quality parameters. While the intent was to ensure product quality prior to market entry, the requirement added complexity and often contributed to processing delays at the NHPD.
Under the updated process, Health Canada no longer requires applicants to submit an FPS alongside their product licence application. The official guidance from Health Canada confirms that this documentation is no longer a mandatory component of the pre-market submission. Companies are still expected to develop and maintain finished product specifications internally as part of their Good Manufacturing Practices (GMP) obligations under the Natural Health Products Regulations (NHPR), but they do not need to provide these documents to the NHPD at the point of application.
Why Health Canada Made This Change
The decision aligns with Health Canada’s ongoing regulatory modernization efforts, which aim to improve efficiency without compromising safety. Over the past several years, the NHPD has faced criticism for lengthy review timelines and a growing backlog of product licence applications. By removing the FPS submission requirement for NHP product licence applications, the directorate intends to focus its review resources on higher-risk aspects of each submission, such as safety and efficacy evidence.
Health Canada has also signalled that this change reflects a greater reliance on site licensing and GMP compliance as mechanisms for ensuring finished product quality. Since licensed NHP manufacturers are already subject to inspection and must maintain product specifications on-site, the regulator has determined that requiring these documents at the application stage represents a duplication of effort. This risk-based approach mirrors trends seen in other Health Canada directorates and in peer regulatory agencies internationally.
What Remains Required in the Application
Although the FPS is no longer part of the submission, applicants must still provide a complete product licence application that meets all other requirements under the NHPR. Key elements of the submission package continue to include:
- Medicinal and non-medicinal ingredient details, including quantities per dosage unit
- Evidence supporting the product’s safety and efficacy claims
- Proper product labelling that complies with NHPR requirements
- A valid site licence number for each manufacturing, packaging, and labelling site
Incomplete applications will still be subject to screening deficiency notices. Companies should ensure that all remaining components are thoroughly prepared to avoid delays during the screening phase.
Impact on Pending and Future Submissions
For companies with applications currently in the NHPD queue, removing the FPS requirement means that any screening deficiency solely due to a missing or incomplete FPS should no longer result in a hold or rejection. However, applicants who have already submitted an FPS as part of their package will not need to take any corrective action, as the document will simply not be reviewed as a standalone requirement.
Going forward, companies preparing new NHP product licence applications can omit the FPS document from their submission packages. This should reduce preparation time and simplify the compilation of application dossiers, particularly for companies managing large product portfolios. That said, the underlying obligation to develop, validate, and maintain finished product specifications under GMP has not changed. Health Canada inspectors may still request these documents during routine or targeted site inspections.
What This Means for Your Business
For NHP companies operating in Canada, this regulatory update offers a meaningful reduction in submission complexity. Product licence applicants can expect a more streamlined preparation process, and the change may contribute to faster screening and review cycles at the NHPD over time. Companies with multiple pending or planned submissions stand to benefit the most, as the cumulative time savings from omitting FPS documentation across a product portfolio can be substantial.
However, this change does not reduce the importance of maintaining rigorous internal quality documentation. Health Canada’s decision to remove the FPS from the pre-market submission process is based on the assumption that licensed manufacturers are already fully meeting their GMP obligations. Companies that have relied on the application process as a forcing function for developing finished product specifications should take this opportunity to audit their internal documentation and ensure that all FPS records are current, validated, and readily accessible for inspection.
Quality Smart Solutions advises NHP companies to review their current submission templates and update their standard operating procedures to reflect this change. Firms that are uncertain about how this update affects their specific applications or internal compliance posture can contact Quality Smart Solutions for guidance tailored to their regulatory situation.
Frequently Asked Questions
Does the removal of the FPS submission requirement mean companies no longer need to create finished product specifications?
This is a common point of confusion following the announcement. The answer is no. Health Canada still requires NHP manufacturers to develop and maintain finished product specifications as part of their GMP obligations under the Natural Health Products Regulations. The change only removes the requirement to include the FPS document in the product licence application submitted to the NHPD. Inspectors may request FPS documentation during site inspections, and companies that fail to maintain these records could face compliance actions.
Will applications that were previously rejected for a missing FPS be reconsidered?
Many applicants who received screening deficiency notices related to FPS documentation are understandably wondering about this. Health Canada has not indicated a blanket policy to retroactively reconsider previously rejected applications solely on this basis. Companies whose applications were refused or placed on hold for FPS-related deficiencies should consult the specific notice they received and, if warranted, contact the NHPD directly to discuss resubmission options under the updated requirements.
How does this change affect NHP applications that include novel ingredients or higher-risk claims?
It is reasonable to wonder whether the FPS exemption applies the same way across all product types. Since the exemption is limited to Class II and Class III NHP product licence applications, applications involving novel ingredients or therapeutic claims are typically handled under a different classification and follow a more detailed safety and efficacy review. For products that do fall under Class II or Class III, the quality-related scrutiny shifts more heavily to the GMP inspection process rather than the pre-market submission stage.
Key Takeaways
- Health Canada has removed the FPS submission requirement for Class II and Class III NHP product licence applications, effective June 25, 2026, under NNHPD Bulletin 11.
- Companies are still required to develop and maintain finished product specifications internally under their GMP obligations.
- All other components of the NHP product licence application remain mandatory, including ingredient details, safety and efficacy evidence, and compliant labelling.
- The change is expected to reduce preparation complexity and may contribute to shorter NHPD review timelines over time.
- NHP manufacturers should audit their internal FPS documentation to ensure inspection readiness, as Health Canada’s quality assurance focus shifts further toward post-market oversight.
Preparing for the Updated Process
This regulatory change represents a practical step forward in Health Canada’s effort to modernize NHP oversight and reduce unnecessary administrative friction. For companies actively managing product licence submissions, now is the time to update internal procedures, confirm that GMP documentation is inspection-ready, and adjust submission templates accordingly.
If you’re preparing an NHP product licence application or want to confirm how this update affects your current submission strategy, our NHP licensing services team can guide you through the process from documentation through Health Canada review. Contact us to discuss your specific situation and ensure your application and quality systems reflect current requirements.
